Rapt Therapeutics appoints Jessica Savage as VP, clinical development

RAPT Therapeutics (RAPT) announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E, a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria. Most recently, Savage served as Senior Medical Director at Alexion, AstraZeneca’s Rare Disease Unit, where she led the clinical development strategy for ALXN2050 in Lupus Nephritis and IgA Nephropathy, overseeing Phase 2 clinical trial execution and preparing for Phase 3.